Bharat Parenterals Ltd receives license from DCGI and CDSCO for manufacturing Favipiravir Oral Suspension

Bharat Parenterals Ltd has received the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of "FAVIPIRAVIR ORAL SUSPENSION l00mg/ml" which will be used for treatment of COVID19 disease.

Further, the product patent has been already filed under fast track approval and the Company is the first one in the Indian Market receiving the license and authorization to manufacture and market "FAVIPIRAVIR ORAL SUSPENSION l00mg/ml".

Shares of Bharat Parenterals Ltd was last trading in BSE at Rs.386.9 as compared to the previous close of Rs. 389.05. The total number of shares traded during the day was 2913 in over 35 trades.

The stock hit an intraday high of Rs. 392 and intraday low of 381.05. The net turnover during the day was Rs. 1121958.

Source : Equity Bulls

Keywords